183 related articles for article (PubMed ID: 21358597)
1. Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: an immunohistochemical study.
Giaginis C; Michailidi C; Stolakis V; Alexandrou P; Tsourouflis G; Klijanienko J; Delladetsima I; Theocharis S
Med Sci Monit; 2011 Feb; 17(3):BR81-90. PubMed ID: 21358597
[TBL] [Abstract][Full Text] [Related]
2. Expression of DNA repair proteins, MSH2, MLH1 and MGMT in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival.
Theocharis S; Klijanienko J; Giaginis C; Rodriguez J; Jouffroy T; Girod A; Point D; Tsourouflis G; Sastre-Garau X
J Oral Pathol Med; 2011 Mar; 40(3):218-26. PubMed ID: 21029181
[TBL] [Abstract][Full Text] [Related]
3. DNA repair proteins may differentiate papillary thyroid cancer from chronic lymphocytic thyroiditis and nodular colloidal goiter.
Evren B; Yılmaz S; Karadağ N; Sertkaya AÇ; Topaloğlu Ö; Kılınç F
Sci Rep; 2021 May; 11(1):9932. PubMed ID: 33976347
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions.
Cooper WA; Kohonen-Corish MR; Chan C; Kwun SY; McCaughan B; Kennedy C; Sutherland RL; Lee CS
Histopathology; 2008 Apr; 52(5):613-22. PubMed ID: 18370958
[TBL] [Abstract][Full Text] [Related]
5. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
[TBL] [Abstract][Full Text] [Related]
6. Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma.
Santos JC; Bastos AU; Cerutti JM; Ribeiro ML
BMC Cancer; 2013 Feb; 13():79. PubMed ID: 23414134
[TBL] [Abstract][Full Text] [Related]
7. [Immunophenotypes and gene mutations in colorectal precancerous lesions and adenocarcinoma].
Huang WT; Qiu T; Ling Y; Shi SS; Guo L; Zheng B; Lü N; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):655-9. PubMed ID: 24433726
[TBL] [Abstract][Full Text] [Related]
8. Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer.
Alkam Y; Mitomi H; Nakai K; Himuro T; Saito T; Takahashi M; Arakawa A; Yao T; Saito M
Histopathology; 2013 Nov; 63(5):713-25. PubMed ID: 24004112
[TBL] [Abstract][Full Text] [Related]
9. Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis.
Sanada M; Hidaka M; Takagi Y; Takano TY; Nakatsu Y; Tsuzuki T; Sekiguchi M
Carcinogenesis; 2007 Dec; 28(12):2657-63. PubMed ID: 17881774
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair genes expression defects & association with clinicopathological characteristics in colorectal carcinoma.
Kaur G; Masoud A; Raihan N; Radzi M; Khamizar W; Kam LS
Indian J Med Res; 2011 Aug; 134(2):186-92. PubMed ID: 21911971
[TBL] [Abstract][Full Text] [Related]
11. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation of different DNA repair genes demonstrates distinct prognostic value for esophageal cancer.
Ling ZQ; Li P; Ge MH; Hu FJ; Fang XH; Dong ZM; Mao WM
Dig Dis Sci; 2011 Oct; 56(10):2992-3004. PubMed ID: 21674174
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
[TBL] [Abstract][Full Text] [Related]
14. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
de Vogel S; Weijenberg MP; Herman JG; Wouters KA; de Goeij AF; van den Brandt PA; de Bruïne AP; van Engeland M
Ann Oncol; 2009 Jul; 20(7):1216-22. PubMed ID: 19164452
[TBL] [Abstract][Full Text] [Related]
15. Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours.
Ruschenburg I; Vollheim B; Stachura J; Cordon-Cardo C; Korabiowska M
Anticancer Res; 2006; 26(3A):2107-12. PubMed ID: 16827152
[TBL] [Abstract][Full Text] [Related]
16. Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
Boeckmann L; Schirmer M; Rosenberger A; Struever D; Thoms KM; Gutzmer R; Has C; Kunz M; Kuschal C; Laspe P; Schoen MP; Brockmoeller J; Emmert S
Pharmacogenet Genomics; 2009 Oct; 19(10):760-9. PubMed ID: 19741564
[TBL] [Abstract][Full Text] [Related]
17. Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases.
Korabiowska M; König F; Verheggen R; Schlott T; Cordon-Cardo C; Romeike B; Brinck U
Anticancer Res; 2004; 24(2B):981-6. PubMed ID: 15161053
[TBL] [Abstract][Full Text] [Related]
18. Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.
Castro GN; Cayado-Gutiérrez N; Zoppino FC; Fanelli MA; Cuello-Carrión FD; Sottile M; Nadin SB; Ciocca DR
Cell Stress Chaperones; 2015 Mar; 20(2):253-65. PubMed ID: 25155585
[TBL] [Abstract][Full Text] [Related]
19. Importance of MutL homologue MLH1 and MutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer.
Erdamar S; Ucaryilmaz E; Demir G; Karahasanoglu T; Dogusoy G; Dirican A; Goksel S
World J Gastroenterol; 2007 Sep; 13(33):4437-44. PubMed ID: 17724798
[TBL] [Abstract][Full Text] [Related]
20. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
